Amgen to invest $1 billion in expanding manufacturing in Puerto Rico

New York, Feb. 2 - Amgen Inc. said it plans to invest $1 billion over the next four years to increase its manufacturing capacity in Puerto Rico.

The company will both expand its existing complex at Juncos, Puerto Rico, and construct a new formulation, fill and finish facility. Around 500 additional employees will be hired by 2010.

The enlargements to current capacity will include the bulk protein manufacturing facility for Neupogen (filgrastim) and Neulasta (pegfilgrastim) and the newly built bulk plant for Epogen (epoetin alfa) and Aranesp (darbepoetin alfa).

On Jan. 24 Amgen announced plans to invest about $1 billion in new bulk protein manufacturing and formulation, fill and finish facilities in Cork, Ireland, to supply European patients. It also said it intends to expand its existing research and development operations in Cambridge, Mass., South San Francisco, Calif., Seattle, and Cambridge, United Kingdom, and build a new development center in Uxbridge, United Kingdom.

Amgen is a Thousand Oaks, Calif., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.